Daily Filing Digest — Monday, 17 Aug 2026

90 filings screened from yesterday's Day Pack, 2 documents pulled to source, 1 cleared the bar. A quiet day — routine corp-action and board-meeting noise made up most of the volume; the deep-brief cross-read (15 briefs) added 3 transcript-backed items the Day Pack alone missed.

Today's filings

• WSFX (WSFx Global Pay) — Q1 FY26-27 investor deck: gross turnover ₹1,491 cr (+36.24% YoY), PAT ₹0.301 cr (+83.82% YoY), but management's own slide flags "structural tailwinds outweighed cyclical headwinds" — FX volatility and study-destination policy risk sit against the growth. (Investor presentation, p.10/p.20)
• VIYASH (Viyash Scientific) — Q1 FY27 call: management quantified the pricing-power gap between its branded formulation business and its commodity API business — "General APIs are going to price erode by 95%. When it comes to oncology or these high potent, we can expect at least 50%-60% price erosion." (Filed transcript, 16-Aug-2026, p.15)
• PARKHOTELS (Apeejay Surrendra Park Hotels) — Q1 FY27 results: 92% occupancy (highest in India per the filing), continued RevPAR leadership in upper-upscale. (Filing, 16-Aug-2026, p.14)
• EMBDL (Embassy Developments) — Q1 FY27 results: revenue ₹217 cr (vs ₹681 cr Q1 FY26), net loss widened to ₹234 cr (vs ₹166 cr); presales up 338% YoY to ₹868 cr. Management cites "trusted and branded developers" positioning in the same call the loss widened — the brand language and the widening loss belong in the same breath, not used as a standalone quote here.

From today's filings

Nothing from today's own Day Pack rose to full-article weight — the two articles published today ("Does Asian Paints Have a Moat?" and "Does Berger Paints Have a Moat?") came from the rotation kit and a fresh AGM transcript found while researching, not from today's filings — said plainly rather than implied. Staged for Sunday's Weekly Filing Digest: VIYASH's pricing-power admission (THE RECEIPTS candidate) and EMBDL's language-vs-numbers gap (THE FINE PRINT candidate, pending primary-PDF verification per that section's mandatory rule).

Educational research, not investment advice. No buy/sell recommendations, no price targets. Moat & Margin is not a SEBI-registered Research Analyst or Investment Adviser.